Preface: the development of hybridomas is essential for the genesis of monoclonal and polyclonal antibodies. So far only the production of monoclonal antibodies has been mentioned. In this scheme, a standard B cell and a neoplastic cell are used. The production of antibodies is the ability of B cells and eternity and the high rate of expansion is the ability of myeloma cells. The antibodies produced are particular in activity. Therefore, the uniform antibody generation strategy is intended as treatment of hybridomas. The method includes six phases. 1. Vaccination: to start, the mice are immunized. Subsequently, the antibody originates against immunization within the mouse body. Whereas, the antibody content is optimal within mice. The splenocytes are immolated and extracted. Splenocyte maintains the production of antibodies against B cells. 2. Coordination: here, the splenocyte is assembled with the cancer cell. Fifty percent of polyethylene glycol is applied to the cells to combine them. A combined cell is targeted as a hybridoma cell. 3. Choice: selection is completed in the middle of the hypothinoidin aminopterin thymidine (HAT). Here you will find the 3 main types of cells. * Cell B without mixing: that can die below medium in a short time because of its short life. * unmixed myeloma cell: which can die inside the medium due to the interruption of the synthesis because it is HGPRT- and Ig-. * Hybridoma cell: will live in the middle due to the activity of B cells. Thus, the hybridoma cell is chosen in this way.4. Screening: it is done by the ELISA system. The selected cells are moved to ninety-six plastic wells. A cell remains in a well. Specific antigens are adsorbed in the lower part of the plates. The antibody binds the antigens if the cells generate the desired antibody. The antibody is then identified by an immunoconjugate containing 2 ingredients. An ingredient is unique to an epitope and the antibody is immobilized by this component. Another is the enzyme that adds color to the well. Once the incubation is complete, the activity of the catalyst is interrupted and the ELISA reader analyzes the optical density. 5. Cloning: once the selection has been made, the cloning of the antibody in the interleukin-6 medium will be attempted for further progress and antibody production. 6. Characterization and storage: antibodies will be placed in liquid medium N2 after characterization.